Core Viewpoint - Baiyang Pharmaceutical has signed a distribution agreement with Guangzhou Junxin Pharmaceutical, granting exclusive rights to promote, sell, and distribute the product Anbomei in specific markets within China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The agreement was signed on November 4, and it outlines the rights and obligations of both parties [1] - Junxin Pharmaceutical is a subsidiary of Jet Bailing (Asia Pacific) Limited, which operates sales in China through Junxin [1] - Baiyang Pharmaceutical aims to provide a comprehensive commercialization solution for Anbomei, enhancing product accessibility and brand value [1]

Core Viewpoint - Baiyang Pharmaceutical (301015) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. on November 4, 2025, granting Baiyang exclusive rights to promote, sell, and distribute the product Anbomei® in a specific market during the agreement period [1]. Group 1 - Baiyang Pharmaceutical will have exclusive promotion and sales rights for Anbomei® [1]. - The agreement was signed on November 4, 2025 [1]. - The partner company in this agreement is Guangzhou Junxin Pharmaceutical Co., Ltd. [1].

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. on November 4, 2025, granting Baiyang exclusive rights to promote, sell, and distribute the product Anbomei® in specific markets during the agreement period [1] Group 1 - The agreement specifies the rights and obligations of both parties involved [1] - Junxin is a subsidiary of Jetabelin (Asia Pacific) Limited, which operates sales in China [1] - Baiyang has been collaborating with Jetabelin on the retail market for Anbomei® since March 2021, and this agreement expands their cooperation into broader retail and hospital markets, excluding specific lists provided by Junxin [1]

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. to enhance cooperation in the human albumin sector, granting Baiyang exclusive rights to promote, sell, and distribute the product Anbomei in specific markets during the agreement period [1]. Group 1 - Baiyang Pharmaceutical and Junxin have formalized their partnership through a distribution agreement signed on November 4, 2025 [1]. - The agreement specifies the rights and obligations of both parties regarding the promotion and distribution of Anbomei [1].

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. to exclusively promote, sell, and distribute the product Anbomei in specific markets within the agreed period [1] Group 1 - The agreement was signed on November 4, 2025, and outlines the rights and obligations of both parties [1] - Junxin is a subsidiary of Jetabellin (Asia Pacific) Limited, which operates sales in China through Junxin [1] - Baiyang Pharmaceutical has been collaborating with Jetabellin on the retail market for Anbomei since March 2021, and this new agreement expands their cooperation into broader retail and hospital markets, excluding specific lists provided by Junxin [1]

Core Viewpoint - The company has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. for the exclusive promotion, sale, and distribution of the product Anbomei® in a specific market during the agreement period [1] Summary by Relevant Sections - **Agreement Details** - The agreement grants the company exclusive rights to promote, sell, and distribute Anbomei® in the designated market [1] - The agreement is effective from November 4, 2025, to June 30, 2035 [1] - **Minimum Purchase Requirements** - For the period from 2025 to 2026, the minimum annual purchase volume is set at 4.5 million bottles [1] - For the period from 2026 to 2027, the minimum annual purchase volume increases to 5 million bottles [1] - For the period from 2027 to 2028, the minimum annual purchase volume further increases to 5.5 million bottles [1]

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次协议签署概况 为加深双方在人血白蛋白领域的合作，青岛百洋医药股份有限公司（以下简 称"公司"或"百洋医药"）与广州市君信药业有限公司（以下简称"君信"）于 2025 年 11 月 4 日签署了《经销协议》，约定君信授予百洋医药在协议期限内在 区域内特定市场独家推广、销售和经销产品安博美®的权利，并对双方权利义务 等作出明确约定。 本次签署协议审批权限在总经理权限范围内，公司已履行了签署本协议的内 部审批程序，无需公司董事会及股东会审议批准。 二、交易合作方介绍 （一）基本情况 青岛百洋医药股份有限公司 企业名称：广州市君信药业有限公司 关于签署经销协议的自愿性信息披露公告 法定代表人：Jean-Marc Jules Morange 注册资本：8,185 万人民币 三、《经销协议》的主要内容 君信：广州市君信药业有限公司 ...

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) disclosed a report regarding the reduction of shares by its controlling shareholder, Baiyang Group, which has triggered a change in shareholding that touches a 5% integer multiple threshold [1][2]. Summary by Sections Share Reduction Plan - Baiyang Group plans to reduce its shareholding by up to 15,768,585 shares, accounting for 3.00% of the total share capital, through centralized bidding and/or block trading from August 12, 2025, to November 11, 2025 [1]. - As of the report date, the reduction plan has not been fully executed [1]. Execution of Share Reduction - From August 12 to August 13, 2025, Baiyang Group reduced its shares by 10,512,390 shares, representing 2.00% of the total share capital through block trading [1]. - From September 11 to November 3, 2025, an additional 1,994,500 shares were reduced through centralized bidding, accounting for 0.38% of the total share capital, leading to a total reduction of 12,506,890 shares [1]. Financial Impact - The average share prices during the reduction period were 26.43 yuan and 28.05 yuan, resulting in a total cash-out amount of approximately 333,788,192.7 yuan [2]. Shareholding Structure - As of the report date, the combined shareholding of the information disclosure obligors decreased to 394,218,110 shares, representing 75.00% of the total share capital, down from 406,725,000 shares, which was 77.46% prior to the reduction [2][3]. - The reduction does not lead to a change in the controlling shareholder or actual controller of the company, nor does it significantly impact the governance structure or future operations of the company [3].

Core Viewpoint - The A-share market saw a collective decline in innovative drug concept stocks, with significant drops in several companies' stock prices, indicating a negative trend in this sector [1]. Group 1: Stock Performance - Changshan Pharmaceutical (300255) experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2]. - Baicheng Pharmaceutical (301096) fell by 7.32%, with a market cap of 6.984 billion and a year-to-date increase of 68.53% [2]. - Baiyang Pharmaceutical (301015) decreased by 7.22%, with a market cap of 13.3 billion and a year-to-date increase of 9.05% [2]. - Other notable declines include: - Bibet-U (688759) down 5.82% with a market cap of 14.3 billion and a year-to-date increase of 79.30% [2]. - Kangchen Pharmaceutical (603590) down 5.81% with a market cap of 7.359 billion and a year-to-date increase of 100.18% [2]. - Kanghong Pharmaceutical (002773) down 5.71% with a market cap of 28.8 billion and a year-to-date increase of 62.53% [2]. - Shanghai Yizhong down 5.48% with a market cap of 11.4 billion and a year-to-date increase of 37.78% [2]. - Guosheng Pharmaceutical (300436) down 5.46% with a market cap of 17.9 billion and a year-to-date increase of 244.35% [2]. - Shenzhou Cell down 5.14% with a market cap of 22.9 billion and a year-to-date increase of 42.06% [2]. - Wanbangde (002082) down 5.07% with a market cap of 8.71 billion and a year-to-date increase of 121.46% [2].